Clinical trials
Prostate Cancer Metastatic Disease clinical trials
Below are recruiting prostate cancer metastatic disease clinical trials, each written for real people, not researchers. We’re tracking 594 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06621173RecruitingEarly Phase 1
Gene therapy for advanced colorectal cancer (dMMR/MSI-H)
This trial tests a new gene therapy (HNF4α SrRNA) given through a vein for people with advanced colorectal cancer that has a specific genetic marker (dMMR or MSI-H). It's for those who have already tried standard treatments without success or couldn't take them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05283044Recruiting
Precision medicine testing for advanced, hard-to-remove cancers
This study helps doctors use more individualized (precision) treatment choices for people with certain advanced cancers. You may be offered study care based on your cancer details, aiming to improve treatment decisions.
BayonneAges 18 years+ - NCT06600698RecruitingPhase 1/Phase 2
Herbal supplement for rising PSA in prostate cancer
This study tests an herbal supplement called AGN-INM176 in men with prostate cancer whose PSA is rising but whose cancer has not spread. It aims to see if the supplement can safely slow PSA rise without the need for hormone therapy or other treatments.
Hershey, PennsylvaniaAges 40 years+ - NCT07240610Recruiting
Radiation and immunotherapy for kidney cancer that has spread
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
Chūō, YamanashiAges 18 years+ - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06260033RecruitingPhase 2
Radiation Therapy for Oligoprogressive ER+ Breast Cancer
This trial tests whether a precise radiation treatment (SBRT) can target a few growing spots of estrogen receptor-positive breast cancer that has spread to other parts of the body. It also uses a special PET scan (FES PET/CT) to see how well the cancer responds. The goal is to slow down the cancer and delay the need for stronger treatments.
Duarte, CaliforniaAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT06276465RecruitingPhase 3
Darolutamide with or without radiation for advanced prostate cancer
This trial tests whether adding radiation therapy to the drug darolutamide helps men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and has spread to a few spots seen on special scans. The study aims to find the best way to control the cancer while keeping side effects manageable.
LorientAges 18 years+ - NCT04780568RecruitingPhase 1
First-line osimertinib plus tegavivint for EGFR-mutant lung cancer
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Columbus, OhioAges 18 years+ - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Boston, MassachusettsAges 18 years+ - NCT07283835RecruitingPhase 2
Study of Cretostimogene for non-muscle invasive bladder cancer
This trial tests a new drug, Cretostimogene, for people with a type of bladder cancer that hasn't spread into the muscle layer (non-muscle invasive) and has not responded to standard BCG treatment. The goal is to see if this drug can help control the cancer and avoid the need for bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05255302RecruitingPhase 2/Phase 3
Shorter immune maintenance for stage IV lung cancer after initial treatment
This trial tests whether giving immune therapy maintenance for a shorter time helps people with stage IV non-small cell lung cancer (NSCLC) who are doing well after initial chemo-immunotherapy. It aims to keep the cancer controlled while possibly reducing treatment exposure and side effects.
Aix-en-ProvenceAges 18–74 - NCT04817956RecruitingPhase 2
Precision-medicine treatment for advanced cancer in Norway
This Phase 2 trial tries to match people with advanced cancer to targeted treatments based on their tumor’s genetic results. It may help if standard cancer treatments are no longer working or aren’t available, and if a “target” in the tumor suggests a therapy that could work.
ÅlesundAges 16 years+ - NCT05884320RecruitingPhase 2
Sacituzumab govitecan for advanced salivary gland cancers
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
Houston, TexasAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new drug to standard care for prostate cancer
This trial tests a new study drug (AAA817) against the usual treatments for men with a certain type of advanced prostate cancer that has spread and is no longer responding to a targeted radiation therapy (177Lu-PSMA). The goal is to see if the new drug can help control the disease longer.
Los Angeles, CaliforniaAges 18–100 - NCT07034053RecruitingPhase 1/Phase 2
Clofarabine for advanced bladder cancer
This trial tests the drug clofarabine in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for those who have already tried standard treatments or chose not to have them.
ViennaAges 18 years+ - NCT05647564Recruiting
PET/CT scan to study why prostate cancer resists treatment
This study uses a PET/CT scan to learn how and why prostate cancer becomes resistant to treatment. It may help researchers better match future therapy choices for people whose prostate cancer is progressing.
Madison, WisconsinAges 18 years+ - NCT07293585RecruitingPhase 3
Precision radiation to protect erectile function in prostate cancer
This trial tests a new radiation technique to better protect erectile function during prostate cancer treatment. It uses advanced imaging to precisely target the tumor while reducing harm to nearby structures.
Los Angeles, CaliforniaAges 18 years+ - NCT06591819RecruitingPhase 2
Shorter pelvic radiation with HDR boost for prostate cancer
This trial tests a shorter course of radiation therapy (hypofractionated whole-pelvis radiation) combined with a high-dose-rate (HDR) brachytherapy boost for men with high-risk or unfavorable intermediate-risk prostate cancer. The goal is to see if this approach controls cancer while possibly reducing side effects.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07129993RecruitingPhase 2/Phase 3
Comparing two drug combinations for advanced bladder cancer
This trial tests a new drug combination (Dato-DXd plus chemotherapy) against a standard chemotherapy combination for advanced bladder cancer that has spread or cannot be removed by surgery. It is for people whose cancer has grown after treatment with the drugs enfortumab vedotin (Padcev) and pembrolizumab (Keytruda).
Fullerton, CaliforniaAges 18 years+ - NCT06542757Recruiting
Focused radiation to main prostate tumor using MRI guidance
This trial tests a stronger, more focused radiation dose to the main tumor inside the prostate using MRI guidance. It aims to improve control of intermediate-risk prostate cancer while possibly reducing side effects.
New York, New YorkAges 18 years+
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer metastatic disease?
- Yes. Clin2 currently lists 594 recruiting prostate cancer metastatic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer metastatic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer metastatic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.